News
Peter Mac recommends Evusheld to help protect vulnerable patients from COVID-19
23 June 2022
Evusheld is an extra COVID-19 medication that provides added protection for vulnerable patients. Peter Mac is recommending this medication for patients with blood cancer, or cancer patients who are immunosuppressed. A clinic at Peter Mac's Parkville location will be administering doses of Evusheld between 27 June and 29 July, 2022. Evusheld protects against all variants of COVID-19 that have been identified to date. Research studies have shown that it may help reduce the risk of COVID-19 infection for at least 6 months. Ask your doctor about whether Evusheld is suitable for you. You can watch a patient information video about Evusheld below, or click here to download the Evusheld Patient Guide. Evusheld is made up of two medications designed to work together against COVID-19. These medications can prevent the virus from entering human cells and reduce the chance of becoming seriously ill due to COVID-19 infection. Evusheld is given in addition to COVID-19 vaccinations and boosters and is not a replacement for them.